



INFORMATION ONLY

Changes to Request Patient Designated Plasma Protein Products for Panhematin®
Customer Letter # 2020-19

2020-05-19

Dear Colleagues:

Further to the previous Customer Letter [2019-21](#), Canadian Blood Services has made an editorial change to the form **Request for Patient Designated Plasma Protein Products**. Please refer to the sample request form attached and image below with highlighted changes. The new change ensures all Panhematin® orders for patients requiring the urgent access will not be limited.

The implementation date for this form is 2020-05-25.

<p>Panhematin <input type="checkbox"/></p> <p>Has the patient already been treated (restock order) <input type="checkbox"/></p> <p>how many were used? _____</p> <p>Size _____</p> <p>Quantity _____</p> <p>or N/A <input type="checkbox"/></p> <p><input type="checkbox"/> Amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.</p> <p><input type="checkbox"/> For urgent need</p>

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier,
Director, Plasma Protein Products Formulary Program